Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature
Cancer Reports · 2024
DOI: 10.1002/cnr2.2142 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Klerize Anecely de Souza Silva und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pós Graduação Ciências da Saúde da Criança e Adolescente, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil. Hauptthemen laut MEDLINE: Vemurafenib, Histiocytosis, Langerhans-Cell, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Langerhans cell histiocytosis (LCH) is a clonal myeloid neoplasm with inflammatory component. Refractory disease is a challenge, but vemurafenib has emerged as a therapeutic option. We will delineate the cases of two Brazilian children suffering from refractory LCH with a positive response to vemurafenib. Cases Both cases had a diagnosis of multisystem disease with involvement of organs at risk and had not responded to standard and second‐line treatment. After refractoriness to classic treatment regimens, the BRAF mutation was investigated and found to be positive in both patients, and target therapy with vemurafenib was sought. The first case has been using vemurafenib for about 2 years and the second case has been using it for about 3 years, having had an attempt to suspend the medication after concomitant use with maintenance therapy. However, the disease returned 4 months after stopping the medication. Fortunately, the disease returned to remission status after the medication was reintroduced.
Conclusion
These cases represent the first reported instances of off‐label vemurafenib use in Brazil for the treatment of LCH and both patients have demonstrated excellent responses to the medication. However, the long‐term side effects are unknown in children, and prospective studies are needed. In addition, there is a lack of epidemiological data on histiocytosis in Brazil and studies evaluating the budgetary impact of incorporating BRAF mutation research and the use of vemurafenib into the public health system. These reports could be a starting point.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pós Graduação Ciências da Saúde da Criança e Adolescente, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
- Hospital da Criança Conceição, Porto Alegre, Brazil.
- Hospital da Criança de Brasília José Alencar, Brasília, Brazil.
ORCID-Profile: Klerize Anecely de Souza Silva, Isis Maria Quezado Soares Magalhães, Daiane Keller Cecconello, Mariana Bohns Michalowski
Zitieren
APA
Silva, K. A. S., Magalhães, I. M. Q. S., Benincasa, D. E. R., Cecconello, D. K., & Michalowski, M. B. (2024). Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature. Cancer Reports. https://doi.org/10.1002/cnr2.2142
Vancouver
Silva KAS, Magalhães IMQS, Benincasa DER, Cecconello DK, Michalowski MB. Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature. Cancer Reports. 2024. doi:10.1002/cnr2.2142
BibTeX
@article{Silva2024,
author = {Silva, Klerize Anecely de Souza and Magalhães, Isis Maria Quezado Soares and Benincasa, Daniela Elaine Roth and Cecconello, Daiane Keller and Michalowski, Mariana Bohns},
title = {Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2142}
}
EUVIMED